Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda
By Sabela Ojea
Shares of Protagonist Therapeutics on Wednesday rose 5.6% to $26.41 in post-market trading after the company signed a worldwide license and collaboration agreement with Takeda for the development and commercialization of rusfertide.
The clinical-stage biopharmaceutical company said it will receive an upfront payment of $300 million, and that it's eligible to receive further payments depending on milestones.
Protagonist will remain responsible for research and development through the completion of the Phase 3 clinical trial for rusfertide and U.S. regulatory approval.
Takeda gets rights for its development, excluding the U.S., and is responsible for leading global commercialization activities.
Rusfertide is aimed at treating Polycythemia Vera, a rare blood disorder.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 31, 2024 18:58 ET (23:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks